Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05588128|
Recruitment Status : Recruiting
First Posted : October 20, 2022
Last Update Posted : March 22, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Prostate cancer is the second leading cause of cancer-related death in American men. The disease recurs in up to 50,000 men each year after their early-stage disease was treated; however, at this stage, imaging scans are often unable to find the disease in the body. In this natural history study, researchers want to find out if a new radiotracer (18F-DCFPyL) injected before positron emission tomography (PET) imaging can help identify sites in the body with cancer.
To learn more about how 18F-DCFPyL PET/CT scans detect change over time in men with recurrent prostate cancer.
Men aged 18 and older with prostate cancer that returned after treatment.
Participants will be screened with blood tests. They will also have a bone scan and a computed tomography (CT) scans of the chest, abdomen, and pelvis.
Participants will have an initial study visit. They will have a physical exam and blood tests. They will have a PET/CT scan with 18F-DCFPyL. The radiotracer will be injected into a vein; this will take about 20 seconds. The PET/CT scan will be done 1 to 2 hours later. Participants will lie still on a scanner table while a machine captures images of their body. The scan will take 45 minutes.
Participants will return for blood tests every 3 months.
Participants will return for additional scans with 18F-DCFPyL on this schedule:
Once a year if their previous scan was negative for prostate cancer.
Every 6 months if their previous scan was positive for prostate cancer.
Participants may be in the study up to 5 years.
|Condition or disease||Intervention/treatment|
|Prostate Cancer Biochemically Recurrent||Drug: 18F-DCFpyL|
- Prostate cancer is the most common malignancy and the second leading cause of cancer- related deaths in American men.
- About 25,000 to 50,000 men each year develop a rising prostate-specific antigen (PSA) after definitive radiation or surgery for early-stage disease but have negative findings on computed tomography (CT) and Tc99 bone scan (standard imaging in prostate cancer).
- The recent Food and Drug Administration (FDA) approval of 18F-DCFPyL PET imaging provides an opportunity to locate micrometastatic lesions in patients with recurrent disease.
- It is unknown how these lesions (or prostate cancer) evolve over time in men with positive findings on 18F-DCFPyL PET imaging.
-To observe participants with biochemically recurrent prostate cancer for 5 years to understand the evolution of 18F-DCFPyL PET lesions in this population.
- History of primary treatment for prostate cancer (either surgery or radiation).
- PSA >= 0.50, and testosterone >100.
- Age >= 18 years.
- No evidence of metastatic soft tissue disease on CT scan (or MRI), or bone lesions on bone scan.
- No androgen deprivation therapy (ADT), no systemic therapy within the 6 months before the study intervention, and no prostatectomy within 1 year before the study intervention.
- Eligible participants will have clinical evaluations and imaging studies. Participants with negative findings on initial/following 18F-DCFPyL scan(s) will be invited every year (+/-2 months) for follow-up imaging studies (including 18F-DCFPyL PET scans). Participants with positive findings on initial/following 18F-DCFPyL scan(s) will be invited every 6 (+/- 1) months for repeat scans, not to exceed 2 scans per year.
- After the initial evaluation, participants will be invited to NIH every 3 months (+/- 2 weeks) for PSA testing.
|Study Type :||Observational|
|Estimated Enrollment :||250 participants|
|Official Title:||A Study of Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18F-DCFPyL|
|Estimated Study Start Date :||March 27, 2023|
|Estimated Primary Completion Date :||December 31, 2024|
|Estimated Study Completion Date :||December 31, 2025|
Participants with biochemically recurrent prostate cancer
Administered to Cohort.
- Observation of 18F-DCFPyL lesions in BRPC [ Time Frame: baseline through 5 years ]Initial 18F-DCFPyL imaging, every 6 months (+/-2 weeks) for participants positive on imaging, and every 12 months (+/- 2 months) for participants negative on imaging until 5 years.
- Progression on 18F-DCFPyL [ Time Frame: baseline through 5 years ]Initial 18F-DCFPyL imaging, every 6 months (+/-2 weeks) for participants positive on imaging, and every 12 months (+/- 2 months) for participants negative on imaging until 5 years.
- Evaluate PSA doubling in association with 18F-DCFPyL changes [ Time Frame: baseline through 5 years ]PSA test every 3 months (+/- 2 weeks) until 5 years.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Male|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- INCLUSION CRITERIA:
- History of primary treatment for prostate cancer (either surgery or radiation)
- Serum PSA >= 0.50
- Serum testosterone >100
- Age >=18 years
- Men must agree to use highly effective contraception (surgical sterilization) for 7 days after every study agent administration. Note: abstinence, defined as no heterosexualsexual intercourse when this is in line with the preferred and usual lifestyle of the subject is also acceptable
- The ability of a participant to understand and the willingness to sign a written informed consent document
-Evidence of soft tissue disease on CT scan (or magnetic resonance imaging [MRI] as clinically indicated).
NOTE: Lymph nodes <= 1.5 cm in the shortest dimension are allowed.
- Evidence of bone lesions on Tc99 bone scan
- Prostatectomy within 1 year before the study intervention
- Androgen deprivation therapy (ADT) within the 6 months before the study intervention
- Systemic therapy for prostate cancer within the 6 months before the study intervention
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05588128
|Contact: Amy R Hankin, P.A.-C||(240) email@example.com|
|Contact: Ravi A Madan, M.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937|
|Principal Investigator:||Ravi A Madan, M.D.||National Cancer Institute (NCI)|
|Responsible Party:||National Cancer Institute (NCI)|
|Other Study ID Numbers:||
|First Posted:||October 20, 2022 Key Record Dates|
|Last Update Posted:||March 22, 2023|
|Last Verified:||March 17, 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||.All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large scale genomic sequencing will be shared with subscribers to dbGAP.|
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
|Time Frame:||Clinical data will be made available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.|
|Access Criteria:||Clinical data will be made available upon request and with the permission of the study PI. Genomic data are made available via dbGaP through requests to the data custodians.|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Cancer Of Prostate
Genital Neoplasms, Male
Neoplasms by Site